Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Zoughbi WA, Kim D, Alperstein SA, Ohara K, Manohar J, Greco N, et al. Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience. Cancer Cytopathol. 2021.

Turajane K, Ji G, Chinenov Y, Chao M, Ayturk U, Suhardi VJ, et al. RNA-seq Analysis of Peri-Implant Tissue Shows Differences in Immune, Notch, Wnt, and Angiogenesis Pathways in Aged Versus Young Mice. JBMR Plus. 2021;5(11):e10535.

Li R, Zeng X, Yang M, Xu X, Feng J, Bao L, et al. Antidiabetic Agent DPP-4i Facilitates Murine Breast Cancer Metastasis by Oncogenic ROS-NRF2-HO-1 Axis via a Positive NRF2-HO-1 Feedback Loop. Front Oncol. 2021;11:679816.

Wang Y, Yan F, Nasar A, Chen Z-, Altorki NK, Stiles B, et al. CUL4 Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. Am J Pathol. 2021;191(9):1638-1650.

Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-644.

Shao R, Zhang Z, Xu Z, Ouyang H, Wang L, Ouyang H, et al. H3K36 methyltransferase NSD1 regulates chondrocyte differentiation for skeletal development and fracture repair. Bone Res. 2021;9(1):30.

Frank SM, Cushing MM. Bleeding, anaemia, and transfusion: an ounce of prevention is worth a pound of cure. Br J Anaesth. 2021;126(1):5-9.

Ranasinha N, Omer A, Philippou Y, Harriss E, Davies L, Chow K, et al. Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI Compass. 2021;2(1):13-23.

Waters KM, Salimian KJ, Assarzadegan N, Hutchings D, Makhoul EP, Windon AL, et al. Cell polarity (the 'four lines') distinguishes gastric dysplasia from epithelial changes in reactive gastropathy. Histopathology. 2021;78(3):453-458.

Fontan L, Goldstein R, Casalena G, Durant M, Teater MR, Wilson J, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021;137(6):788-800.